Top 5 Takeaways Significant Increase in Heat-Related Illnesses: Emergency department (ED) visits for heat-related illnesses in the U.S. spiked during May–September 2023, especially among males and adults aged 18–64. Impact
Tag: 2024
Top 5 Takeaways Risk of Salmonellosis in Newborns: A case of neonatal salmonellosis in Oregon highlights the risks to newborns from backyard poultry, even without direct exposure, emphasizing the dangers
Top 5 Takeaways Low incidence of sudden cardiac death post-vaccination: Among 1,292 deaths of Oregon residents aged 16–30 during the study period, only three sudden deaths occurred within 100 days
Top 5 Takeaways Significant Increase in Infections: After switching to Medtronic Duet EVD systems, Rhode Island Hospital observed a threefold increase in positive cerebrospinal fluid (CSF) cultures and an eightfold
Top 5 Takeaways Significant Increase in Vaccine Supply: From 2021 to 2023, COVID-19 vaccine doses received in the African Region increased from 321 million to 860 million, with 646 million
Top 5 Takeaways Increased Comprehensive Coverage: From 2018 to 2022, states with comprehensive Medicaid coverage of tobacco cessation treatments rose from 15 to 20, while those without any treatment access
Top 5 Takeaways Significant Increase in Cases Early 2024: There was a dramatic rise in reported measles cases in the first quarter of 2024, with 97 new cases accounting for
Top 5 Takeaways Significant Contribution by FRPP: The Federal Retail Pharmacy Program (FRPP) partners administered 67.7% of the 59.8 million COVID-19 bivalent vaccine doses in the U.S. during the study
Top 5 Takeaways Global Surveillance Enhancements: In 2022–2023, 71.4% of 28 priority countries met national acute flaccid paralysis (AFP) surveillance indicator targets, and environmental surveillance sites increased, supporting the global
Top 5 Takeaways Increased Protection for Immunocompromised Adults: The updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccine offers increased protection against COVID-19-associated hospitalizations for adults aged ≥18 years with immunocompromising conditions. Low